Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 4241-4250 Newer>

BusinessWeek October 29, 2007 Arlene Weintraub	Heart Trouble The tiny stent sparked a lucrative industry - and made Dr. Samin Sharma a star. Then questions arose about the device's safety and efficacy.
BusinessWeek October 29, 2007 Catherine Arnst	Superbugs: Where Are the Wonder Drugs? Antibiotics are losing the battle against superbugs, and drugmakers are slow to replenish the arsenal.
BusinessWeek October 29, 2007 Arlene Weintraub	When Good Buzz Goes Bad How Xtent is weathering safety worries about medicated stents.
BusinessWeek October 29, 2007 Arlene Weintraub	Medtronic's Uncertain Endeavor The drug-coated stent might have made up for Medtronic's recent product recall, but renewed scrutiny of the device has executives scaling back expectations
The Motley Fool October 18, 2007 Brian Orelli	Amylin: Waiting on the Future Research and development costs drag down the drug developer's bottom line. Investors, take note.
The Motley Fool October 18, 2007 Brian Lawler	Genzyme Shows Off a Drug Candidate A top compound in development could become an important MS treatment.
IndustryWeek November 1, 2007 Jill Jusko	IBM Takes 3-D Innovation to the Doctor's Office Researchers unveil prototype software that lets physicians better visualize medical data.
The Motley Fool October 17, 2007 Brian Orelli	FDA Warning Might Be a Buying Opportunity The 3%-4% drops in the stock prices of Amylin and Alkermes, Amylin's partner in the development of a sustained-release version of Byetta, could be a good buying opportunity for investors.
The Motley Fool October 16, 2007 Billy Fisher	Forest Labs Isn't Out of the Woods Yet The drugmaker's Q2 profit falls, but the company raises its full-year forecast.
The Motley Fool October 16, 2007 Brian Orelli	Pozen Hedges Its Bets As promised, Pozen and partner GlaxoSmithKline announce that the pair have submitted a response to their approvable letter for Trexima, and that they plan to do an additional just-in-case safety trial.
<Older 4241-4250 Newer> Return to current articles.